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Abstract
Histamine H1 and serotonin 5-HT2A receptors present in the CNS have been implicated in various
neuropsychiatric disorders. 9-Aminomethyl-9,10-dihydroanthracene (AMDA), a conformationally
constrained diarylalkyl amine derivative, has affinity for both of these receptors. A structure-
affinity relationship (SAFIR) study was carried out studying the effects of N-methylation, varying
the linker chain length and constraint of the aromatic rings on the binding affinities of the
compounds with the 5-HT2A and H1 receptors. Homology modeling of the 5-HT2A and H1
receptors suggests that AMDA and its analogs, the parent of which is a 5-HT2A antagonist, can
bind in a fashion analogous to that of classical H1 antagonists whose ring systems are oriented
towards the fifth and sixth transmembrane helices. The modeled orientation of the ligands are
consistent with the reported site-directed mutagenesis data for 5-HT2A and H1 receptors and
provide a potential explanation for the selectivity of ligands acting at both receptors.
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1. Introduction
Sleep disorders and circadian rhythm abnormalities are prevalent, with 70 million
Americans reporting disturbed sleep each year. Epidemiological studies indicate that
between 30–48% of the global population find difficulty in initiating and maintaining sleep.1
Serotonin (5-hydroxytryptamine, 5-HT), a major neurotransmitter found in the CNS and
periphery, has been reported to be involved in the control of sleep and waking states.2 5-HT2
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receptors belong to the superfamily of G protein-coupled receptors (GPCRs) and consist of
three subtypes: 2A, 2B and 2C. 5-HT2A receptors are involved mainly in non-rapid eye
movement sleep regulation and respiratory control,3 and selective antagonism of the 5-HT2A
receptor has emerged as a promising new mechanism for the treatment of sleep disorders.4
Histamine released by tissue mast cells, basophils and histaminergic neurons is also known
to impact the ability to fall asleep and stay asleep.5 It has been suggested that ligands acting
at H1 receptors in the CNS may be useful in the treatment of neuropsychiatric and sleep
disorders.6 Histamine exerts its effect by interacting with four different receptors H1-H4,
which are GPCRs.7,8 Early research and development of H1 ligands has focused largely on
antagonists that are used for their antiallergic effects in the periphery. However, first-
generation H1 receptor antagonists (diphenhydramine, mepyramine, chlorpheniramine) also
exhibit high H1 receptor occupancy in the CNS due in part to their lipophilicity, leading to
sedative effects.9–11 This led to the development of second-generation antagonists
(acrivastine, loratadine, terfenadine, cetirizine, etc.) that exhibited high selectivity and less
sedative potential due to the decrease in their ability to penetrate the blood brain barrier.12,13
Some of these antagonists (doxepin, ketotifen, epinastine, olopatadine), which have a tri- or
tetracyclic fused ring system, also showed affinity at 5-HT2A, adrenaline α1, dopamine D2
and muscarinic M1 receptors, indicative of their low selectivity for the H1 receptor.14
Among the various chemical classes of H1 antagonists, ligands that are zwitterionic
(olopatadine, acrivastine, fexofenadine) showed the highest degree of selectivity for H1,
suggesting that the carboxylate group of the ligand may interact with a residue (K191)15 in
the H1 receptor that is not present in the other GPCRs. Introduction of a carboxylate moiety
thus provides one potential means of designing peripherally-acting H1-selective antagonists.
In this study, we set out to determine if H1 versus 5-HT2A selectivity could be achieved
through the systematic modification of the uncharacteristically nonpolar16 structure of 9-
(aminomethyl)-9,10-dihydroanthracene (AMDA, 1a). We have previously reported AMDA
as the parent member of a potentially new class of high-affinity 5-HT2A antagonists.17,18
This work builds on our earlier studies19 by creating a “matrix” of AMDA-like compounds
in which the aromatic ring system, degree of N-methylation and length of the aliphatic linker
are systematically varied. A series of 9-(aminoalkyl)-9,10-dihydroanthracenes (DHAs) and
an analogous series of diphenylalkylamines (DPAs) were synthesized and their binding
affinities at H1 and 5-HT2A determined. Our results show that AMDA and related
compounds exhibit varying degrees of affinity for the H1 receptor. Homology models using
the human β2-adrenoceptor (β2-AR)20 as a template provide receptor-based explanations for
the observed structure-affinity relationships (SAFIR) among the AMDA analogs. To our
knowledge this is also the first report of a comparison of 5-HT2A and H1 homology models
generated from the β2-adrenergic structure.
2. Results and discussion
2.1. Chemistry
9-(Aminomethyl)-9,10-dihydroanthracene (1a), 9-(2-aminoethyl)-9,10-dihydroanthracene
(2a) and 9-(2-aminopropyl)-9,10-dihydroanthracene (3a) were prepared as previously
described.19,21 N-Alkylated analogs 1b, 1c, 3b and 3c have been reported by us.19 N-
Methylated analogs of 2a were synthesized (Scheme 1) using 9-hydroxymethylanthracene 7
as the starting material. Halogenation22 followed by cyanation23 of the alcohol gave 2-
(anthracen-9-yl)acetonitrile 9 that was further hydrolyzed to the corresponding acid 10.
Anthracene ring reduction using sodium metal in n-pentanol gave 2-(9,10-
dihydroanthracen-9-yl)acetic acid (11). Sequential conversion of the acid 11 to its amide 12
via acid chloride, followed by reduction, afforded 2-(9,10-dihydroanthracen-9-yl)-N-
methylethanamine (2b). 2-(9,10-Dihydroanthracen-9-yl)-N,N-dimethylethanamine (2c) was
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obtained by reductive amination24 of 2-(9,10-dihydroanthracen-9-yl)acetaldehyde (15),
which was obtained by the oxidation of 2-(9,10-dihydroanthracen-9-yl)ethanol (14) (Scheme
2). N-Methyl-2,2-diphenylethanamine25 (4b) was obtained by the N-methylation of the
respective amine as reported.26 N,N-Dimethyl-3,3-diphenylpropan-1-amine27 (5c) was
obtained by the same method adopted for the synthesis of 2c from commercially available
3,3-diphenylpropanal. 4,4-Diphenylbutan-1-amine28 (6a) was obtained by the BH3·THF
reduction of commercially available 4,4-diphenylbutanenitrile. Compounds 4a, 4c, 5a, 5b,
6b, and 6c were commercially obtained.
2.2. Structure-affinity relationships
Several reviews describing structure-activity relationship studies of diphenhydramine-like
antihistamines have been reported.29–31 The features that have been systematically varied
include the nature of the two required aromatic groups, the terminal basic amine and the
aliphatic linker between these two features.32,33 In this work, we examined similar structural
variations using AMDA as the parent structure. These compounds closely resemble well-
established H1 antagonists: replacement of the ether oxygen of diphenhydramine by a
methylene unit results in compound 6c and replacement of the pyridin-2-yl group of the H1
antagonist pheniramine with a phenyl group results in 5c.
Compound affinities for the 5-HT2A and H1 receptors are given in Table 1 and displayed
graphically in Fig. 1. The most significant differences in affinity were observed between the
9-(aminoalkyl)-9,10-dihydroanthracene (DHA) compounds (Fig. 1a) and their
corresponding diphenylalkylamine (DPA) congeners (Fig. 1b). Ring-opening of the tricyclic
system uniformly produced decreases in affinity for both 5-HT2A and H1 receptors. No DPA
compound exhibited high affinity (Ki < 100 nM) at 5-HT2A, and only three showed high
affinity for H1 receptors (5b, Ki = 64 nM; 5c, Ki = 75 nM; 6c, Ki = 70 nM). In contrast,
many of the DHA analogs were found to have high affinity at both receptors, demonstrating
that dihydroanthracene is a privileged34 structure. For compounds interacting with the H1
receptor, progressively increasing either the number of methylene units in the linker or the
number of N-methyl groups consistently retained or enhanced affinity in both the DHA and
the DPA series. H1 receptor affinity was insensitive to chain length for the unsubstituted
amine analogs of AMDA (1a, Ki = 197 nM; 2a, Ki = 137 nM; 3a, Ki = 175 nM). In contrast,
H1 affinity increased with increasing chain length for both N-methylated (1b, Ki = 189 nM;
2b, Ki = 48 nM; 3b, Ki = 3 nM) and N,N-dimethylated analogs (1c, Ki = 25 nM; 2c, Ki = 6
nM; 3c, Ki = 0.5 nM). For the DHA analogs, N,N-dimethylation and a three-methylene
linker was optimal for H1 affinity (3c, Ki = 0.5 nM). The trends in affinity at 5-HT2A are
less uniform. Like the H1 receptor, the affinity of the DPA compounds for 5-HT2A generally
increased with increasing linker length or degree of N-methylation though, as noted above,
no DPA compound was found to have substantial (Ki < 700 nM) affinity for the 5-HT2A
receptor. As observed previously for DHA19 and compounds with a one-methylene linker,
5-HT2A affinity decreased as N-methylation degree increased (1a, Ki = 20 nM; 1b, Ki = 52
nM; 1c, Ki = 540 nM). This trend was not observed for the other linker lengths.
Additionally, for DHA compounds with no N-methylation, linker lengths of one (1a, Ki = 20
nM) and three (3a, Ki = 32 nM) methylene units demonstrated significantly higher affinity
than the two-methylene linker (2a, Ki = 480 nM) compound. Affinities were more uniform
for compounds with one N-methyl group (1b, Ki = 52 nM; 2b, Ki = 92 nM; 3b, Ki = 13 nM),
and for those with two N-methyl groups, affinity increased with linker length by 25-fold (1c,
Ki = 540 nM; 2c, Ki = 84 nM; 3c, Ki = 22 nM). In general, 5-HT2A receptor affinity is less
sensitive to N-methylation and chain length variation than H1 receptor affinity.
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2.3. Modeling receptor-ligand interactions
2.3.1. H1 and 5-HT2A receptor models—When considering the selectivity of a
particular ligand for one receptor versus another, it is useful to analyze the differences in
amino acids that comprise the binding sites of the two receptors. The alignment of the
human H1 and 5-HT2A receptor sequences with that of human β2-AR is presented in Fig. 2.
The H1 receptor is phylogenetically related to the 5-HT2 receptor subtypes, with higher
sequence homology found primarily in the transmembrane-spanning regions.35 Based on the
primary sequences, binding site analysis of both 5-HT2A and H1 receptors indicates that the
major variations in amino acid constitution occur at positions 3.33, xl2.52, xl2.54, 5.39,
5.42, 6.55 and 7.35 (Fig. 2). Differences in steric and electrostatic sidechain properties at
these and other positions are likely responsible for directing the ligand selectivity of the two
receptors. The H1 receptor amino acid residue K1915.39, not commonly found at this
position among aminergic GPCRs, could be potentially exploited for the design of highly
selective H1 ligands. The three-dimensional arrangement of these residues is shown in Fig.
3. The residues that are conserved between H1 and 5-HT2A are those that tend to be highly
conserved among all aminergic GPCRs. These residues, primarily located in the inner region
of the binding cavity, include W3.28, the amine counter-ion D3.32, S3.36 and T3.37, and the
‘aromatic cluster’ 36–39 residues W6.48 and F6.52, and Y7.43 (an H-bonding partner for
D3.32).
Models of human H1 and 5-HT2A receptors were generated with the MODELLER40
program using a high-resolution crystal structure of the human β2-AR20 as the template (see
Experimental Methods). Inspection of putative receptor binding sites and ligand binding
modes in our homology models (Figs. 4 and 5) indicate two common interactions that occur
for each of the compounds listed in Table 1 at both 5-HT2A and H1 receptors: 1) the highly
conserved aspartic acid residue at position41 3.32 (H1, D1073.32; 5-HT2A, D1553.32) is able
to interact with the protonated amine of the docked ligand; and 2) hydrophobic residues
present in transmembrane helix 6 (TM6) comprising the aromatic cluster42 are able to
interact with the aromatic rings of the ligands. In other binding site locations variability of
amino acid residues at equivalent positions in the hH1 and h5-HT2A receptors influence the
way the aromatic rings are oriented in the receptor, which in turn provides an explanation
for the observed differences in affinity for AMDA and its analogs with varying chain
lengths. The presence of hydrophobic residues surrounding the conserved D3.32 in H1 and in
5-HT2A, together with the aromatic cluster region in H1 and in 5-HT2A, provide sites of
favorable interaction with the ligands for each receptor.
2.3.3. Binding mode analysis—Compounds listed in Table 1 were docked into the
receptor binding sites of the H1 and 5-HT2A receptor models using the GOLD automated
docking routine.43 The GOLD scoring function (steric and electrostatic interactions) was
used to select the favored ligand conformation. In addition, we carried out HINT44
(Hydropathic INTeraction) analysis to characterize the nature of the binding site
interactions. HINT is a free-energy-based method that considers atom-atom interactions in a
bimolecular complex using a parameter set derived from octanol/water partition
coefficients.45 Modeling observations indicate that the compounds prefer to be oriented
within the binding pockets of the two receptor models in similar, but distinct binding modes
(see Figures 4 and 5). The well-known aspartate D3.32 residue was found to interact with the
basic amine in both receptors for each docked ligand, and the ligand aromatic rings were
consistently oriented in the binding site surrounded by TM4, TM5 and TM6. In general, for
the short-chain linker ligands there is a relatively small amount of ligand surface area that
may interact with the surrounding hydrophobic environment in the binding pocket,
accounting for the observed decreased affinity of these compounds at both 5-HT2A and H1
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(Figs. 4c and 5c). However, for AMDA (1a), the observed high affinity could be due to the
presence of an alternate binding mode.46
The tricyclic DHA ring system in 3c showed strong hydrophobic interactions (Y1083.33,
L1634.61, F168xl2.38, F1905.38 and F4356.55), with the phenyl rings oriented toward TM5
and the aliphatic linker located deep in the H1 binding pocket. In contrast, in the 5-HT2A
model, 3c is oriented such that the phenyl rings are facing TM6 (F3396.51, F3406.52 and
N3436.55) and the aliphatic linker is positioned closer to extracellular loop 2 (EL2). For both
H1 and 5-HT2A, the compound with the longest linker and highest degree of methylation
(3c) was found to have the highest (H1) or one of the highest (5-HT2A) affinities among the
compounds tested. The methylene linkers in the H1 receptor are able to interact with
residues L1043.29 and Y4316.51, which explains the comparatively higher affinity of 3c for
H1 than for 5-HT2A. Further, the observed differences in ligand orientation within the
receptor binding site can account for the preference for N-methylation at H1, with the methyl
groups more closely surrounded by hydrophobic residues as compared to 5-HT2A (Figs. 4a
and 5a).
For the unbridged DPA analogs, the increased conformational flexibility (as compared to
DHA) and intramolecular steric repulsion produce a twisted ring orientation. This results in
more unfavorable receptor-ligand interactions (steric clashes and polar-nonpolar
interactions) involving the ring system and the surrounding residues (Figs. 4b and 5b).
HINT hydropathic interaction analysis provided additional support for the proposed
orientation of the ligands in the binding pocket. Fig. 6 shows the HINT maps generated for
compound 3c (which has the highest affinity for both receptors) in the binding sites of the
H1 and 5-HT2A receptors. In each case the tricyclic ring system fits into the hydrophobic
‘aromatic cluster’ while the amine group faces D1073.32 and is stabilized by both ionic and
hydrogen bonding interactions. However, both the aliphatic linker region and the N-methyl
groups engage in more extensive hydrophobic interactions in H1 than in 5-HT2A.
In addition, the receptor-ligand complexes described here are in general agreement with
other studies that have implicated residues that contribute to an antagonist binding site in H1
and 5-HT2A. Besides the several key residues that have been reported by site-directed
mutagenesis studies in H1 receptor models15,47 (W1584.56, Y2005.48, F4246.44, W4286.48,
F4326.52 and F4356.55) and 5-HT2A receptor models48 (F2435.47, W3366.48, F3396.51,
F3406.52), we found that Y1083.33 and I4547.39 were oriented to favorably interact with
ligands in the binding pocket of the H1 receptor, and the cognate residues V1563.33 and
V3667.39 for the 5-HT2A receptor. The differences in the stereoelectronic character of these
residues likely contribute to the differences in the way the ligand binds to these receptors,
and consequently the observed differences in binding affinity.
3. Conclusions
Within the matrix of compounds synthesized and tested, the N,N-dimethylated chain-
lengthened propylene analog of AMDA shows the highest affinity at both 5-HT2A and H1
receptors (3c: 5-HT2A, Ki = 22 nM; H1, Ki = 0.5 nM) and the highest selectivity for the H1
receptor (44-fold). In addition, removing the conformational restriction of the
dihydroanthracene tricyclic system by ring-opening to provide a diphenyl system is
detrimental to the ligand affinity for both 5-HT2A and H1 receptors. Structure-affinity
relationships among these compounds show that N-alkylation either decreases or has little
effect on 5-HT2A affinity, while the propylene linker is the optimum chain length between
the tricyclic system and amine for receptor affinity. Modeling studies suggest that diaryl
alkylamine analogs exhibit a common binding mode within the 5-HT2A and H1 receptors.
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Hydropathic analysis of the modeled complexes supports the proposed role of the TM6
aromatic cluster in directing binding. The proposed differences in the binding pocket of H1
(Y1083.33 and I4547.39) and 5-HT2A (V1563.33 and V3667.39) may determine the way
ligands bind, which in turn may determine the selectivity of the ligands for each of the two
receptors. These preliminary modeling results provide a qualitative understanding of how
AMDA analogs might interact with the 5-HT2A and H1 receptors. This study also provides
potential insight into the mechanisms by which differences in the structures of the receptors
and ligands determines receptor selectivity. We continue to synthesize and test compounds




Nuclear magnetic resonance (1H NMR and 13C NMR) spectra were recorded using a Varian
Gemini 300 spectrometer in CDCl3 using tetramethylsilane as an internal standard unless
otherwise specified. Melting points were determined using an OptiMelt melting point
apparatus and are uncorrected. Elemental analyses were performed by Atlantic Microlab,
Inc., and determined values are within 0.4% of theory. All reactions were maintained under
a nitrogen atmosphere. Anhydrous solvents were purchased and stored under nitrogen over
molecular sieves. Medium-pressure column chromatography was carried out using silica gel
60 Å, 0.040–0.063 mm, (200–400 mesh), Sorbent Technologies.
4.1.1. 9-Bromomethylanthracene (8).22—Phosphorus tribromide (0.8 ml, 8.4 mmol)
was added to a suspension of 9-hydroxymethylanthracene 7 (1.5 g, 7.2 mmol) in toluene (40
ml) at 0 °C via syringe. The mixture was stirred at 0 °C for 1 h and then warmed to rt,
during which the reaction became homogeneous. Saturated Na2CO3 solution (15 mL) was
added slowly and the reaction mixture was stirred until it cooled to rt. The phases were
separated, and the organic phase was washed with H2O (10 mL), brine (10 mL) and dried
over MgSO4. The yellow filtrate was concentrated to minimum volume, and then stored at 0
°C for crystallization. The yellow needle-like solid was collected and dried in vacuum (1.24
g). The mother liquid was concentrated and purified using medium pressure column
chromatography (0.6 g). The two parts were combined to give the product 8 (total 1.84 g,
94%) as yellow solid. mp 143 – 146 °C. 1H NMR (300 MHz, CDCl3): δ 5.3 (s, 2H, CH2-
Br), 7.2 – 8.3 (m, 9H, Ar-H). 13C NMR (75 MHz, CDCl3): δ 32.20, 125.50, 125.70, 125.80,
127.70, 128.10, 129.40, 131.60.
4.1.2. 2-(Anthracen-9-yl)acetonitrile (9)—A solution of 9-bromomethylanthracene 8
(1.5 g, 5.53 mmol) in DMSO (15 mL) was added over 10 min to a stirred suspension of
KCN (0.54 g, 8.29 mmol) in DMSO (30 mL) at 70 °C under N2. The mixture was stirred for
an additional 40 min, cooled to rt, and diluted with H2O. The aqueous layer was saturated
with NaCl and then extracted with ether (3 × 25 mL). The combined extracts were washed
with H2O, dried (MgSO4), filtered, and concentrated to yield solid product 9 (0.96 g, 80%).
mp 154 – 156 °C. 1H NMR (300 MHz, CDCl3): δ 4.6 (s, 2H, CH2-CN), 7.2–8.5 (m, 9H, Ar-
H). 13C NMR (75 MHz, CDCl3): δ 20.50, 125.20, 125.31, 124.60, 126.10, 128.20, 130.10,
131.60.
4.1.3. 2-(Anthracen-9-yl)acetic acid (10)—KOH (0.97 g, 17.48 mmol) in 10 ml of H2O
was added to a suspension of 2-(anthracen-9-yl)acetonitrile 9 (0.95 g, 4.37 mmol) in
ethylene glycol (50 ml). The mixture was heated at reflux for 24 h until homogenous. The
hot solution was filtered, and the filtrate was acidified with dilute HCl to obtain the
precipitated product 10 (1.0 g, 100%). mp 228 – 230 °C. 1H NMR (300 MHz, CDCl3): δ 4.2
Shah et al. Page 6













(s, 2H, CH2), 7.5 – 8.5 (m, 9H, Ar-H). 13C-NMR (75 MHz, CDCl3): δ 34.20, 124.60,
125.30, 125.60, 126.10, 128.20, 130.50, 131.90, 173.40.
4.1.4 2-(9,10-Dihydroanthracen-9-yl)acetic acid (11)—Sodium metal (10 equiv) was
added slowly to a refluxing solution of 2-(anthracen-9-yl)acetic acid 10 (0.9 g, 3.8 mmol) in
1-pentanol (20 ml). The reaction mixture was stirred for 10 min until all of the sodium
dissolved, then was cooled and H2O (10 mL) was added. The solution was made acidic with
5% HCl. The reaction mixture was concentrated under vacuum and the oily solution
obtained was triturated with chloroform, dried (MgSO4) and concentrated to yield pure
product 4 (0.76 g, 84%). 1H NMR (300 MHz, CDCl3): δ 2.8 (d, J = 7.8 Hz 2H, CH2), 4.4 (t,
J = 7.8 Hz, 1H, CH), 3.9 (d, J = 18.1 Hz, 2H, Ar-CH2-Ar), 4.1 (d, J = 18.1 Hz, 2H, ArCH2-
Ar), 7.1–7.3 (m, 8H, Ar-H). 13C-NMR (75 MHz, CDCl3): δ 40.1, 41.2, 45.1, 126.8, 128.7,
138.4, 139.6, 177.4.
4.1.5. 2-(9,10-Dihydroanthracen-9-yl)-N-methylacetamide (12)—Thionyl chloride
(1.73 g, 14.6 mmol) was added under N2 to a stirred solution of compound 11 (0.7 g, 2.9
mmol) in anhydrous benzene (5 mL). The solution was heated at reflux (2 h), allowed to
cool and the excess benzene and thionyl chloride were removed under reduced pressure to
provide an oil. The oil obtained was dissolved in anhydrous THF (10 mL) and cooled in an
ice bath (0 °C). A methylamine/THF (2 M, 5.8 mmol) solution was added dropwise into the
stirred solution, and the mixture was stirred at rt (2 h). The solvent was removed under
reduced pressure to give a white solid. Water (20 mL) was added, and the suspension was
extracted with EtOAc (3 × 25 mL). The combined extracts were washed with water, brine
and dried (MgSO4). Removal of solvent under reduced pressure gave the crude amide as a
viscous oil. The resulting amide was purified using medium pressure chromatography
(CH2Cl2/acetone, 9:1), yield (75–80%). 1H NMR (300 MHz, CDCl3): δ 2.45 (s, 3H, CH3), δ
2.67 (d, J = 7.8 Hz, 2H, CH2), 3.93 (d, J = 18.3 Hz, 2H, Ar-CH2-Ar), 4.05 (d, J = 18.3 Hz,
2H, Ar-CH2-Ar), 4.56 (t, J = 7.5 Hz, 1H, CH), 7.16–7.37 (m, 8H, Ar-H). 13C-NMR (75
MHz, CDCl3): δ 34.79, 41.0, 41.6, 42.60 126.11, 127.47, 135.91, 138.24, 176.58.
4.1.6. 2-(9,10-Dihydroanthracen-9-yl)-N-methylethanamine (2b)—A borane-THF
complex (1.0 M in THF, 0.537 g, 6.25 mmol) was added in a dropwise manner to a stirred
solution of 12 (0.35 g, 1.25 mmol) in anhydrous THF (5 mL) under N2 at 0 °C. The mixture
was slowly warmed to rt and heated at reflux (6 h). The reaction mixture was allowed to
cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture was heated at reflux
(1 h) and allowed to cool to rt, and the solvent was removed under reduced pressure. Water
was added and the residue was extracted with ether (25 mL). The aqueous portion was made
basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The organic layer was
washed with water and brine, dried (MgSO4), and concentrated under reduced pressure to
give 2b, which was then purified by medium pressure column chromatography. CH2Cl2/
MeOH (9:1) yield (80–85%). mp 202 – 205 °C (oxalate). 1H-NMR (300 MHz, CDCl3): δ
1.81 (q, J = 7.5 Hz, 2H, CH2), 2.38 (s, 3H, CH3), 2.56 (t, J = 7.5 Hz, 2H, CH2-NH), 3.89 (d,
J = 18.3 Hz, 1H, Ar-CH2-Ar), 4.09 (d, J = 18.3 Hz, 1H, Ar-CH2-Ar), 4.03 (t, J = 7.2 Hz, 1H,
Ar-CH-Ar), 7.1 – 7.3 (m, 8H, Ar-H). 13C-NMR (75 MHz, CDCl3): δ 35.30, 36.72, 37.40,
45.41, 50.20, 126.41, 128.10, 136.40, 140.61. Anal. (C17H19N·C2H2O4·0.25 H2O): C, H, N.
4.1.7. 2-(9,10-Dihydroanthracen-9-yl)ethanol (14)—Na2K silica gel (2 g) was added
to a well-stirred solution of 2-(anthracen-9-yl)ethanol 13 (0.75 g, 4.4 mmol) in anhydrous
THF and stirred continuously under nitrogen. The reaction mixture was refluxed for 15 min
then allowed to cool to rt and quenched with H2O (50 mL). The solid precipitate was filtered
and washed with EtOAc (5 × 25 mL). The filtrate was then collected followed by extraction.
The EtOAc portion was dried (MgSO4) and concentrated under reduced pressure to provide
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viscous yellow oil. The resulting yellow oil was purified using medium pressure column
chromatography (CH2Cl2/MeOH, 9:1) to provide 14 (0.65 g, 86%) as a yellow oil. 1H-NMR
(300 MHz, CDCl3): δ 1.86 (m, 2H, CH2), δ 3.61 (t, 2H, CH2-OH), 3.90 (d, J = 18.3 Hz, 2H,
Ar-CH2-Ar), 3.95 (d, J = 18.3 Hz, 1H, Ar-CH2-Ar), 4.0 (d, J = 18.3 Hz, 1H, Ar-CH2-Ar),
4.02 (t, J = 7.5 Hz, 1H, CH), 7.19 – 7.47 (m, 8H, Ar-H). 13C-NMR (75 MHz, CDCl3): δ
31.29, 31.39, 52.1, 62.30 126.11, 128.47, 137.91, 138.24.
4.1.8. 2-(9,10-Dihydroanthracen-9-yl)acetaldehyde (15)—A solution of (9,10-
dihydroanthracene-9-yl)ethanol 14 (0.60 g, 1.5 mmol) dissolved in anhydrous CH2Cl2 (20
mL) was added to a stirred mixture of Dess-Martin oxidant (0.954 g, 2.25 mmol) in CH2Cl2.
The reaction mixture was stirred for 1 h, then diluted with ether (75 mL) and poured into 1.3
M NaOH (75 mL). The ether layer was separated and extracted with 1.3 M NaOH (3 × 15
mL) and was washed with H2O (2 × 20 mL), brine (20 mL), dried (MgSO4) and
concentrated under reduced pressure to yield an oil. The resulting oil was purified using
medium pressure column chromatography (petroleum ether/EtOAc 9:1) to provide 15 (0.445
g, 75%) as an oil. 1H NMR (300 MHz, CDCl3): δ 2.69 (d, 2H, CH2-CHO), 3.87 (d, J = 18.3
Hz, 1H, Ar-CH2-Ar), 4.06 (d, J = 18.3 Hz, 1H, Ar-CH2-Ar), 4.55 (t, J = 6.9 Hz, 1H, CH),
7.19 – 7.34 (m, 8H, Ar-H) 9.71 (s, 1H, CHO), 13C NMR (75 MHz, CDCl3): δ 34.85, 40.77,
50.0, 126.19, 127.54, 137.21, 138.50.
4.1.9. 2-(9,10-Dihydroanthracen-9-yl)-N,N-dimethylethanamine oxalate (2c)—2-
(9,10-Dihydroanthracene-9-yl)acetaldehyde 15 (0.4 g, 1.79 mmol), dimethylamine
hydrochloride (0.292 g, 3.59 mmol) and titanium isopropoxide (1.02 g, 3.59 mmol) were
added to a solution of triethylamine (0.363 g, 3.59 mmol) in absolute ethanol. The reaction
mixture was stirred at rt for 12 h. NaBH3 (0.1 g, 2.68 mmol) was then added and the mixture
was stirred for 12 h. The reaction was quenched by pouring the mixture into aqueous
ammonia (30 mL, 2 N). The resulting precipitate was filtered and washed with CH2Cl2 (5 ×
20 mL). The filtrate was collected and extracted with CH2Cl2. The CH2Cl2 portion was
dried (MgSO4) and concentrated under reduced pressure to provide viscous yellow oil. The
resulting yellow oil was purified using medium pressure column chromatography (CH2Cl2/
MeOH, 9:1) to provide 2c (0.248 g, 55%). The yellow oil was dissolved in anhydrous
acetone (10 mL) and oxalic acid (0.043 g, 0.47 mmol) was added until no further precipitate
formed. The oxalate salt was recrystallized from methanol/ether to provide 2c oxalate as
pale yellow crystals. Yield (55%). mp 183 – 185 °C (oxalate). 1H-NMR (300 MHz, CDCl3):
δ 1.83 (q, J = 7.5 Hz, 2H, CH2), 2.26 (s, 6H, (CH3)2), 2.28 – 2.30 (m, 2H, CH2-N), 3.94 (d,
J = 18.6 Hz, 1H, Ar-CH2-Ar), 4.14 (d, J = 18.6 Hz, 1H, Ar-CH2-Ar), 4.1 (t, J = 7.2 Hz, 1H,
CH), 7.1 – 7.3 (m, 8H, Ar-H). 13C-NMR (75 MHz, CDCl3): δ 32.30, 40.41, 45.32, 52.20,
56.21, 126.80, 128.71, 138.42, 140.10. Anal. (C18H21N·C2H2O4·0.5 H2O): C, H, N.
4.1.10. N-methyl-2,2-diphenylethanamine (4b)—Yield (50%). mp 149 – 151 °C
(oxalate) 1H-NMR (300 MHz, CDCl3): δ 2.47 (s, 3H, CH3), 3.02 (d, J = 8.1 Hz, 2H, CH2),
4.3 (t, J = 6 Hz, 1H, Ar-CH-Ar), 7.12 – 7.26 (m, 10H, Ar-H). 13C-NMR (75 MHz, CDCl3):
δ 37.20, 44.80, 60.20, 126.60, 128.50, 129.60, 143.0. Anal. (C15H17N·C2H2O4): C, H, N.
4.1.11. N,N-dimethyl-3,3-diphenylpropan-1-amine (5c)—Yield (20%). mp 150 –
153 °C (oxalate) 1H-NMR (300 MHz, CDCl3): δ 2.52 – 2.56 (m, 2H, CH2), 2.85 (s, 6H,
(CH3)2), 3.0 – 3.02 (m, 2H, CH2-N), 4.2 (t, J = 7.4 Hz, 1H, Ar-CH-Ar), 7.2 – 7.4 (m, 10H,
Ar-H). 13C-NMR (75 MHz, CDCl3): δ 32.20, 45.80, 50.60, 58.33, 126.30, 128.20, 129.10,
143.15. Anal. (C17H21N·C2H2O4·0.5 H2O): C, H, N.
4.1.12. 4,4-diphenylbutan-1-amine (6a)—Yield (60%). mp 198 – 200 °C (HCl) 1H-
NMR (300 MHz, CDCl3): δ 1.42 – 1.48 (m, 2H, CH2), 2.03 – 2.1 (m, 2H, CH2), 2.73 (t, J =
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6.2 Hz 2H, CH2-NH2), 4.1 (t, J = 7.2 Hz, 1H, Ar-CH-Ar), 7.1 – 7.3 (m, 10H, Ar-H). 13C-
NMR (75 MHz, CDCl3): δ 32.30, 38.40, 42.30, 52.20, 126.80, 128.70, 129.40, 143.10. Anal.
(C16H19N·0.5 HCl): C, H, N.
4.2. Molecular modeling
Molecular modeling investigations were conducted using the SYBYL 7.1 molecular
modeling package (Tripos LP, St. Louis, MO) on MIPS R14K- and R16K-based IRIX 6.5
Silicon Graphics Fuel and Tezro workstations. Molecular mechanics-based energy
minimizations were performed using the Tripos Force Field with Gasteiger-Hückel charges,
a distance-dependent dielectric constant (ε = 4) and a non-bonded interaction cutoff of 8 Å
and were terminated at an energy gradient of 0.05 kcal/(mol×Å). The hH1 (P35367) and h5-
HT2A (P28233) receptor sequences were retrieved from the ExPASy Proteomics Server
(http://www.expasy.org/) and aligned with a profile of several related class A GPCRs
(human, dopamine D3 (P35462), muscarinic cholinergic M1 (P11229), vasopressin V1a
(P37288), adrenergic β2 (P07550), δ-opioid (P41143), 5-HT2A (P28223), dopamine D2
(P14416), bovine rhodopsin (P02699) using the ClustalX program.49 Within ClustalX, the
slow-accurate alignment algorithm was used, the BLOSUM matrix series was employed and
the gap opening penalty was increased from 10.0 to 15.0 to help maintain the continuity of
the transmembrane helical segments. The alignment was carried out in two separate steps as
reported by Bissantz, et al.50 Manual adjustment of the ClustalX alignment was required to
properly align the disulfide-forming cysteine residues in the EL2 loop. The result was an
unambiguous alignment in the transmembrane (TM) helical regions of both the hH1 and h5-
HT2A sequences with that of the β2–adrenoceptor. This alignment, along with a file
containing the atomic coordinates of the adrenergic β2 receptor (PDB ID = 2RH1), was used
as input to the MODELLER40 software package to generate a population of 100 different
hH1 or h5-HT2A homology models. Each of these receptors was subsequently energy-
minimized.
The automated docking program GOLD43 version 3.01 (Cambridge Crystallographic Data
Centre, Cambridge, UK) was then used to dock the classical antihistaminic
diphenhydramine and the high-affinity ligands 3c and AMDA (1a) from the synthesized
dihydroanthracene matrix into each of the 100 receptor models using the ChemScore fitness
function. Based on the fitness function values, steric and electronic interactions of the
docked poses and reported site-directed mutagenesis data, one receptor model was selected
to represent the ligand binding site of the hH1 and h5-HT2A receptors. These models were
subsequently analyzed using PROCHECK51 and the ProTable facility within SYBYL to
assess the geometric integrity of various structural elements (bond lengths, torsion angles,
etc.) of each receptor model. After checks for stereochemical integrity, the receptor models
were used for the docking of all the target compounds. Ligand molecules were created
within SYBYL and energy-minimized using the same parameters as were used for the
receptor models. Basic amines were protonated to form ammonium ions. GOLD was used to
dock each resulting ligand structure (using the parameter set defined by the “standard default
settings” option) into the final receptor model. Each receptor-ligand complex was then
energy-minimized with its best-ranked docking pose.
The HINT scoring function was utilized (version 3.12) to explore and visualize hydropathic
interactions by analyzing the ligand-receptor complexes generated by the automated docking
program GOLD. The interaction scores were calculated for the highest-ranked ligand
conformation. The receptors (5-HT2A and H1) and ligands were partitioned as distinct
molecules. The ‘all hydrogen atoms’ option was employed in the H-bonding model, and
hydrogen atoms at unsaturated positions and alpha to heteroatoms were considered potential
H-bond donors. The inferred solvent model, which considers the partition of each residue
based on its hydrogen count, was selected. The ‘Chain HBond Correction’ option was set to
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‘+20 –NH– SASA’. Finally, hydrophobic and polar interaction HINT maps were generated
separately at +20% of the maximum HINT value.
4.3. Affinity determinations
Binding assays and data analysis were performed through the NIMH Psychoactive Drug
Screening Program (PDSP) using cloned human receptors. The 5-HT2A competitive binding
assay employs [3H]ketanserin (a 5-HT2A antagonist) as the radioligand, and the H1
competitive binding assay employs [3H]chlorpheniramine (an H1 antagonist) as the
radioligand. Binding data were analyzed using Prism (GraphPad Software, Inc., San Diego,
CA). Details of the binding assay protocol may be found at the PDSP home page,
http://pdsp.med.unc.edu.
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3D bar graph showing the affinities at 5-HT2A and H1 for the a) 9-(aminoalkyl)-9,10-
dihydroanthracene (DHA) and b) diphenylalkylamine (DPA) analogs listed in Table 1.
Shah et al. Page 13














Alignment of the human β2-adrenergic, H1 and 5-HT2A receptor sequences. Sequence
positions highlighted in pink indicate highly conserved amino acids among the Class A
GPCR family that serve as reference positions in the Ballesteros-Weinstein52 numbering
system, as well as the cysteine residues of the disulfide bridge tethering EL2 to TM3. The
traditional numbering shown corresponds to the hH1 (top) and h5-HT2A (bottom) sequences.
β2-Adrenergic residues highlighted in purple indicate positions in the third intracellular loop
(IL3) that were mutated to glycine in the hH1 and h5-HT2A sequences; these were retained
in subsequent hH1 and h5-HT2A models. Other residues highlighted in the hH1 and h5-HT2A
sequences represent the residues of the binding site and correspond to those positions that
are within 5.0 Å of the carazolol ligand bound in the β2AR homolog. The color indicates the
degree of similarity between the hH1 and h5-HT2A residue at a particular position as defined
by the Gonnet PAM250 similarity matrix (green = identical; yellow = strong or weak
conservation; red = no conservation). The figure was created using ALSCRIPT.53
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Illustration of the differences in binding site residue composition of the hH1 and h5-HT2A
receptors within the context of the β2AR-T4L crystal structure. Residues are truncated at the
Cβ carbon atom (ball-and-stick representation) and are colored based on residue similarity as
described in Fig. 2. For those positions whose residue identity differs, the H1 residue is
listed first, followed by the 5-HT2A residue.
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Docked hH1-ligand complexes. a) 3c. b) 6c. c) 1a. Residues within 5 Å of the bound ligand
are displayed.
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Docked h5-HT2A-ligand complexes. b) 3c. b) 6c. c) 1a. Residues within 5 Å of the bound
ligand are displayed.
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HINT interaction maps for compound 3c in a) H1 and b) 5-HT2A binding sites. Regions of
favorable hydrophobic (green) and polar (magenta) intermolecular interactions are shown as
contours.
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(a) PBr3, toluene 0 °C, 1 h; (b) KCN, DMSO, 70 °C, 1 h; (c) KOH, ethylene glycol:H2O
(1:1), reflux, 12 h; (d) Na, 1-pentanol, reflux, 30 min; (e) SOCl2, dry benzene, reflux, 2 h; (f)
methylamine-THF, 25 °C, 6 h; (g) BH3·THF, THF reflux, 6 h.
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(a) Na2K silica gel, THF, 1 h; (b) Dess-Martin reagent, CH2Cl2, 1 h; (c) Me2NH HCl, Ti(O-
i-Pr)4, NEt3, Abs. EtOH, 25 °C, 9 h, NaBH4, 25 °C, 10 h.
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